Document Detail


Prevention of coronary heart disease with statins. Which patients profit?
MedLine Citation:
PMID:  12891851     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Statins are generally considered as safe drugs with a very favorable cost-efficacy-ratio. Calculation of health expenses limits the prescription of statins in primary prevention to persons on high risk (i.e. 20% risk of a coronary infarction within the next 10 years). Prescription of statins in secondary prevention of atherosclerosis is mandatory. Advanced age, impairment of renal function or polypharmacotherapy increase the incidence of severe side-effects, especially myopathy and rhabdomyolysis. These patients should be given statins with lesser risk of these side-effects. Combination of statins with fibrates has attracted public concern, but may be indicated in persons with otherwise not treatable hyperlipidemia. These patients need intensive monitoring, just as patients on other drugs that are metabolized via the enzyme CYP3A4. Patients on statins should get dietary counseling, as an appropriate diet increases the effect of statins.
Authors:
O Adam; W Forth
Publication Detail:
Type:  English Abstract; Journal Article    
Journal Detail:
Title:  MMW Fortschritte der Medizin     Volume:  145     ISSN:  1438-3276     ISO Abbreviation:  MMW Fortschr Med     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-08-01     Completed Date:  2004-01-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100893959     Medline TA:  MMW Fortschr Med     Country:  Germany    
Other Details:
Languages:  ger     Pagination:  37-40     Citation Subset:  IM    
Affiliation:
Walther-Straub-Institut für Pharmakologie und Toxikologie der LMU München. olaf.adam@lrz.uni-muenchen.de
Vernacular Title:
KHK-Prävention mit Statinen. Welche Patienten profitieren?
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / adverse effects,  therapeutic use*
Coronary Disease / prevention & control*
Germany
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Hypercholesterolemia / drug therapy
Myocardial Infarction / prevention & control
Patient Acceptance of Health Care
Recurrence / prevention & control
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surgical therapy of breast carcinoma. Much of the fright is lost
Next Document:  Issues of causality in the history of occupational epidemiology.